AACR Annual Meeting 2018 - Insphero

AACR Annual Meeting 2018


Apr 14 - 18, 2018

Enabling Innovative Cancer Science

jump to section

Meet InSphero Oncology Experts at AACR 2018 to learn how you can gain greater translational insights using our 3D™ InSight assay ready tumor models and services.

  • Receive highly predictive 3D models that mimic complex in vitro tumor microenvironment, delivered assay-ready to your lab
  • Discover more with tailored oncology services for drug efficacy testing and immuno-oncology
  • Rely on ISO 9001:2015 quality-controlled microtissues
  • Reduce animal testing with a pharma-validated 3D liver model

Schedule a Meeting

We combine tumor, stromal, and immune components to produce custom-designed 3D in vitro models that better reflect human cancer biology

Search for Cures with Tailored Oncology Services

Talk to our team at AACR to learn how we can work for you. 3D InSight™ Oncology Services combine the predictive power of our physiologically relevant cell-line and PDX tumor models with the 3D applications expertise of our scientific staff.

  • Custom tumor model development
  • Efficacy testing
  • Combinatorial Drug Testing
  • Tumor Relapse Assay
  • Antibody Penetration

Conference Detail

  • Conference Dates: April 14-18, 2018
  • Venue: McCormick Place North/South, Chicago, IL USA
  • Booth: 938

jump to section
jump to section

Poster Presentation

Late-Breaking Research; Tumor Biology 1

Sunday, April 15, 1 – 5 PM, Poster Section 45, Number LB-034/3
Development and characterization of PDX-derived 3D tumor microtissues as platform for screening targeted molecular therapeutics
A major issue for improving the overall success rate in drug development is the lack of accurate experimental human in vitro models. While there is a significant and increasing need for such better ex vivo cell-based models, the question on how closely these systems resemble and recapitulate the original tumors is of great importance. Patient-derived xenograft (PDX) models act as vehicle systems to propagate human tumor specimens, faithfully preserving the biological features and the genetic expression profile. The retainment of such criteria in in vitro 3D InSight™ Tumor Microtissues derived from PDX lines is crucial to provide a relevant physiological environment and strategy to assess candidate drugs for novel therapeutic approaches. Here, we show that development and characterization of in vitro 3D InSight™ Tumor Microtissues from patient-derived xenograft (PDX) lines demonstrate that the morphological and molecular features of the parental tumors are well retained. We suggest that in vitro 3D PDX models offer a more suitable and robust approach to expedite faithful efficacy assessment and approval of optimal drug candidates.

In Booth Posters

InSphero In-Booth Posters

April 15-18, during exhibit hours, Exhibition Hall Booth 938

  • Akura™ Flow: A Microfluidic Multi-Tissue Platform Engineered for 3D InSight™ Microtissues
  • Accelerate Drug Discovery and Development with the InSphero Oncology Platform